Decision: Favourable

Study Title:

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

  • NREC Code:


  • Decision:


  • Meeting Date:


  • Study Type:

    CT application

  • Principal Investigator:

    Prof Douglas Veale

  • PI Institution:

    St Vincent's University Hospital

  • Sponsor:

    Bristol Myers Squibb International Corporation

Scroll to Top